Tab%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520linagliptin

# Linagliptin ## Overview Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations, stimulating glucose-dependent insulin release and decreasing glucagon levels. It is unique among DPP-4 inhibitors as its primary route of elimination is biliary/fecal, requiring no dose adjustments for renal or hepatic impairment. ## Primary Indications Type 2 diabetes mellitus (as an adjunct to diet and exercise to improve glycemic control). ## Adult Dosing * **Standard Dose:** 5 mg orally once daily. * **Maximum Dose:** 5 mg/day. ## Pediatric Dosing * **Safety and Efficacy:** Not established for patients under 18 years of age. * **Clinical Note:** DPP-4 inhibitors are generally not first-line therapy for pediatric type 2 diabetes. ## Dose Adjustments * **Renal Impairment:** No dose adjustment required regardless of CrCl. * **Hepatic Impairment:** No dose adjustment required. ## Contraindications * Hypersensitivity to linagliptin (e.g., anaphylaxis, angioedema, exfoliative skin conditions). ## Adverse Effects * **Common:** Nasopharyngitis, hypoglycemia (when used with insulin or secretagogues, e.g., sulfonylureas). * **Serious:** Acute pancreatitis (discontinue if suspected), severe and disabling arthralgia, bullous pemphigoid, hypersensitivity reactions. ## Key Drug Interactions * **Strong P-gp/CYP3A4 Inducers (e.g., Rifampin):** May decrease linagliptin efficacy. Avoid concurrent use if possible; increase monitoring if combined. * **Insulin/Sulfonylureas:** Increased risk of hypoglycemia; consider dose reduction of the insulin secretagogue. ## Monitoring * **HbA1c:** Every 3–6 months. * **Glucose:** Self-monitoring of blood glucose (SMBG). * **Clinical:** Monitor for signs/symptoms of pancreatitis (persistent, severe abdominal pain) and bullous pemphigoid (blistering or erosions). ## Clinical Pearls * **PK Profile:** Linagliptin exhibits non-linear protein binding. Its pharmacokinetic profile is minimally affected by renal function, making it a preferred agent for patients with advanced chronic kidney disease or dialysis. * **Administration:** May be taken with or without food. * **Weight/BP:** Weight-neutral and generally does not affect blood pressure. * **Combination:** Often available as a fixed-dose combination with metformin (Jentadueto) or empagliflozin (Glyxambi). *** *Disclaimer: This information is for educational purposes and does not replace professional clinical judgment. Prescribing practices and local guidelines may vary. Always verify current prescribing information via the manufacturer’s label or an authoritative clinical database (e.g., Lexicomp, UpToDate) before initiation.*